Why Eli Lilly (LLY) Rose 6.63% on October 29, 2026 After Q3 Earnings

Eli Lilly and Company (NYSE: LLY) closed at $1,373.70 on Thursday, October 29, 2026, a 6.63% gain from its $1,288.30 close on October 28. The advance followed the drugmaker's third-quarter results, which showed strong demand for Mounjaro and Zepbound and a substantially higher full-year revenue forecast. That is a well-supported explanation for why the earnings announcement attracted buyers, although a daily share-price change cannot be assigned to one cause with certainty.

Importantly, this is a look back at a completed trading session, not a live stock quotation. LLY then finished Friday, October 30, at $1,417.54, up another 3.19% from October 29. Those are two distinct daily gains. The shares trade on the New York Stock Exchange in U.S. dollars.

The October 29 move, with dates and prices separated

The October 29 percentage is calculated as ($1,373.70 − $1,288.30) ÷ $1,288.30, rounded to two decimal places. The supplied delayed market-data snapshot was timestamped October 29 at 20:03:18 UTC, equivalent to 4:03:18 p.m. in New York on Eastern Daylight Time (EDT, UTC−04:00). That quote timestamp is not the earnings-call time or the official market closing bell. The regular NYSE trading session ended at 4:00 p.m. EDT (20:00 UTC). For historical price verification, readers can consult Lilly's historic stock-price lookup; displayed data may be delayed.

What Lilly actually reported on October 29

Lilly's October 29 third-quarter earnings release reported revenue of $24.397 billion, up 39% from $17.601 billion a year earlier. The company reported diluted earnings per share of $7.22, compared with $6.21 in the year-earlier quarter. Its non-GAAP EPS, using the company's stated adjustments, was $7.48, versus $7.02 a year earlier.

These are company-reported results, not estimates of what traders expected. Lilly said worldwide revenue benefited from a 53% increase in volume while realized prices declined by 15%. The combination helps explain the distinction between expanding demand and pressure on the average price received. Because mix and other factors affect reported revenue, those percentage movements should not be treated as a simple mathematical bridge.

Mounjaro and Zepbound remained the largest sales drivers

Mounjaro generated $10.723 billion of worldwide third-quarter revenue, up 65% year over year. Zepbound contributed $5.352 billion, up 49%. Lilly attributed both brands' growth primarily to strong demand, with lower realized prices partly offsetting volume gains. Mounjaro's sales outside the United States rose 93% to approximately $5.7 billion; the company also noted pricing effects from its inclusion on China's National Reimbursement Drug List.

For investors trying to explain the October 29 response, these brand-level figures matter more than a generic description of the obesity-drug market. They show how much of Lilly's current business expansion was tied to medicines already generating substantial revenue, rather than only to candidates that may reach the market later.

The full-year revenue forecast rose sharply

Perhaps the clearest forward-looking change in the release was the 2026 revenue guidance increase from $85 billion–$87 billion to $91 billion–$92 billion. The new midpoint, $91.5 billion, is $5.5 billion above the old midpoint of $86 billion. Lilly also raised its forecast performance-margin range from 49.0%–50.5% to 52.0%–52.5%.

Higher sales guidance is an important candidate explanation for the positive market reaction: it signals that management expected stronger full-year revenue than it had previously projected. It is still a forecast, not booked sales, and the closing price alone does not reveal how much weight each investor assigned to it.

The details that temper the upbeat headline

The earnings release also contains caveats. Lilly said the quarter included roughly $900 million in benefits, primarily from $410 million of Jardiance milestone payments and favorable revisions to estimates for rebates and discounts. The company said no further Jardiance milestones remained under the cited arrangement. These benefits are real reported revenue, but readers should not assume they will repeat at the same level every quarter.

In addition, Lilly's updated 2026 non-GAAP EPS guidance was $35.00–$36.00, compared with the prior $35.50–$36.50 range. The company explained that a $4.07 increase in underlying non-GAAP EPS guidance at the midpoint was more than offset by $4.57 in acquired in-process research and development (IPR&D) charges from third-quarter business-development activity. Both reported and non-GAAP third-quarter EPS included those acquired IPR&D charges. Describing the overall earnings outlook simply as 'raised' would therefore be misleading.

Those costs sit alongside strategic investments that may or may not produce future returns. Lilly discussed regulatory progress and its research pipeline, including retatrutide results, in the same release. Pipeline progress can support expectations, but it should not be equated with an approved indication, future sales, or a guaranteed stock-price effect. Further financial details and risk discussion appear in Lilly's Form 10-Q for the quarter ended September 30, 2026.

A hypothetical shareholder's way to read the rally

Illustrative example only: Imagine a fictional shareholder, Alex, who held 10 LLY shares throughout October 28–30 and did not trade. At the October 28 closing price, that position had a market value of $12,883. At the October 29 closing price, it was worth $13,737, an unrealized increase of $854 over one session. At the October 30 close, the same 10 shares had a market value of $14,175.40, a further $438.40 increase from the preceding close.

This example does not describe a real investor or a tested trading strategy. It isolates what the verified closing prices mean for a fixed share count, excluding dividends, transaction costs, taxes and any actual purchase price. Alex's next question should not be 'Does a 6.63% rise guarantee another rally?' It should be 'Which of the earnings developments might justify higher expectations, and which could prove temporary?'

A practical review would place the new $91 billion–$92 billion sales outlook beside the previous range, read the Mounjaro and Zepbound growth rates alongside the decline in realized prices, and note the one-time or estimate-related revenue benefits. That approach explains the investment narrative without turning the example into a buy or sell recommendation.

Why the reaction can be explained, but not proven

The sequence is clear: Lilly announced strong third-quarter sales and higher 2026 revenue guidance on October 29, and its stock posted a 6.63% regular-session gain. These disclosures are plausible and material contributors to the move. They are not proof that each order was placed for the same reason, and price action alone cannot distinguish earnings-driven buying from positioning, broader market moves, or other forces.

Lilly had also announced positive topline retatrutide trial results on October 28, before earnings day. That separate disclosure provides nearby context but should not be automatically credited with a specific portion of the October 29 share-price gain. The company described the results in its October 28 clinical-trial announcement.

What to watch after the two completed sessions

As of the end of Friday, October 30, LLY had gained on two consecutive sessions, but that historical observation is not a prediction. The next scheduled regular NYSE trading day is Monday, November 2, 2026, subject to exchange operations. Because clocks in New York return to standard time on Sunday, November 1, the normal market opening would be 9:30 a.m. New York Eastern Standard Time (EST, UTC−05:00), or 14:30 UTC, rather than the October 29 opening's EDT offset.

Any further move would depend on new information and investor reassessment. Relevant follow-up questions include whether strong treatment demand continues to outweigh realized-price pressure, how much of the upgraded revenue outlook comes from recurring operations, and how development spending affects future earnings. An investor should consult the official Lilly quarterly-results materials for the underlying disclosures rather than extrapolate a future price from two positive days.

Bottom line: The October 29, 2026 LLY rally followed a quarter of 39% revenue growth, robust Mounjaro and Zepbound sales, and a substantial upward revision to annual revenue guidance. Acquired IPR&D charges, nonrecurring revenue benefits and pricing pressure are essential qualifications. October 30's 3.19% rise was a separate completed session. This article explains the historical market response and does not provide personalized investment advice.